{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} A Review of COVID-19 Chilblains-like Lesions and their Differential Diagnosis
Activity Steps
Purpose of Activity
To familiarize wound care practitioners with the differential diagnoses of chilblains-like lesions that could be associated with the complications of COVID-19.Learning Objectives
After completing this continuing education activity you will be able to:
- Identify the population most often affected by COVID toes.
- Select the assessments that help differentiate the various conditions that cause chilblains-like lesions.
- Choose appropriate treatment options for the various conditions that cause chilblains-like lesions.
Disclosures
Dr Lara-Corrales is part of the Pediatric Dermatology Research Alliance COVID-19 Response Task Force, a collaboration between the Society for Pediatric Dermatology and the Pediatric Dermatology Research Alliance. She has also disclosed ongoing financial relationships with Abbvie & Sanofi Genzyme as well as past relationships with Johnson & Johnson, Avicanna, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Pierre Fabre, Regeneron, Clementia, and Valeant. Dr Sibbald has disclosed past financial relationships with Novartis, Pfizer & Sanofi Genzyme. Lippincott CME Institute has identified and resolved all conflicts of interest concerning this educational activity. The remaining authors, faculty, staff, and planners, including spouses/partners (if any), in any position to control the content of this CME/NCPD activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies relevant to this educational activity.
Credits:
- ANCC 2.0 CH / 0.5 APH
- DC - BON 2.0 CH
- FL - BON 2.0 CH
- GA - BON 2.0 CH
Awarded Advanced Pharmacology Hours